• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PAA
Click for more information
2.78% 18.5¢

PHARMAUST LIMITED - News & Media

Market Cap $73.24M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare

PharmAust Limited is a clinical-stage biotechnology company developing therapeutics for... PharmAust Limited is a clinical-stage biotechnology company developing therapeutics for human and animal health applications. The Company’s segments include Corporate and Research. The Company is focused on repurposing monepantel (MPL) for human neurodegenerative diseases. The Company's lead candidate, Monepantel (MPL), is a potent and safe inhibitor of the mTOR pathway, that plays a central role in cell growth and proliferation of cancer cells and in degenerating neurons. The Company is also developing MPL as a treatment for motor neuron disease (MND/ALS), a rare, incurable disease. It is focused on starting Phase II/III clinical study of MPL. It has also completed a Phase II oncology clinical study of MPL in humans and pilot studies in canine cancer. It is also preparing a pivotal monepantel field trial in dogs with B-Cell Lymphoma to enable product registration in the United States.More

Articles & Videos

PharmAust CEO's sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of its CEO, Dr. Michael Thurn.

23 Apr 2024 12:08 (AEST)

PharmAust teams up with Berry Consultants for phase 2/3 MND study

PharmAust (ASX:PAA) is collaborating with renowned clinical study design expert, Berry Consultants, to design and analyse its planned phase 2/3 study for monepantel in patients with MND and ALS.

16 Jan 2024 13:34 (AEDT)

Pharmaust completes Phase One Monepantel study and files for Orphan Drug Designation

Pharmaust (ASX:PAA) has announced that all patients have completed its phase one MEND study using monepantel (MPL) to test its functions on Motor Neuron Disease (MND).

01 Dec 2023 11:32 (AEDT)

PharmAust completes dosing in phase one MND trial

Pharmaust (ASX:PAA) has finished dosing all patients in cohort four of its phase one MEND study using monepantel (MPL) to treat Motor Neurone Disease.

13 Oct 2023 10:50 (AEDT)

PharmAust (ASX:PAA) welcomes Dr Michael Thurn as new CEO

PharmAust (ASX:PAA) has appointed Dr Michael Thurn as its newest Chief Executive Officer, starting from September 1.

28 Aug 2023 15:09 (AEST)

PharmAust's (ASX:PAA) phase one trial indicates MPL's potential to slow MND progression

Pharmaust (ASX:PAA) has reported that its phase one trial using the lead drug, MPL, for MND/ALS has successfully slowed disease progression in 11 out of 12 patients.

22 Aug 2023 11:41 (AEST)

PharmAust's (ASX:PAA) subsidiary Epichem enters voluntary liquidation

PharmAust (ASX:PAA) has appointed joint and several liquidators from Grant Thornton Australia, to administer the creditor's voluntary winding-up proceedings for PAA's subsidiary, Epichem.

01 Aug 2023 13:39 (AEST)

PharmAust's (ASX:PAA) Beagle patient surpasses one year on MPL

PharmAust’s (ASX:PAA) patient, Louie the Beagle, has surpassed one year of treatment with the company’s Monepantel (MPL) drug.

06 Jul 2023 13:42 (AEST)

PharmAust (ASX:PAA) reports positive preliminary data in MND/ALS trial

PharmAust (ASX:PAA) has released preliminary data from its phase 1/2 trial assessing its lead drug candidate MPL in MND/ALS0.

04 Jul 2023 16:25 (AEST)

PharmAust (ASX:PAA) escalates dosage of third patient cohort in MND/ALS trial

PharmAust (ASX:PAA) has announced that all 12 patients in cohort three have received an initial escalated dose in its phase one/two trial of MPL in MND and ALS.

27 Jun 2023 13:46 (AEST)



(20min delay)
Last
18.5¢ 		Change
0.005(2.78%) 		Mkt cap ! $73.24M
Open High Low Value Volume
18.5¢ 19.0¢ 18.3¢ $334.1K 1.802M

Buyers (Bids)

No. Vol. Price($)
2 111778 18.5¢
 

Sellers (Offers)

Price($) Vol. No.
19.0¢ 104266 4
View Market Depth
Last trade - 16.10pm 16/05/2024 (20 minute delay) ?
Last
18.5¢ 		  Change
0.005 ( 2.78 %)
Open High Low Volume
18.5¢ 19.0¢ 18.0¢ 1184237
Last updated 15.57pm 16/05/2024 ?
PAA (ASX) Chart

Top Stories

Greentech and Anax team up to put Whim Creek copper hub on steroids

GreenTech Metals and Anax Metals are set to sign a memorandum of understanding to strategise processing and development of key copper assets.
After long delays, Mantle Minerals kicks off drillrun for gold at Mt Berghaus After delays borne from tenement disputes with rail operators, Mantle Minerals has kicked off drilling at its Mt. Berghaus tenements in WA.
The home PC changed retail stores forever. Shekel Brainweigh can do it again Retail store automation demands tech to prevent shoplifting and give business owners peace of mind. Shekel Brainweigh does just that.
Market Close: Green light launches ASX lift off as US inflation ebbs The ASX200 closed nearly 1.6% up. Every sector @ aside from energy @ ended in the green.In the greenThe real estate sector had a stellar day… gaining 3.4 percent @ with Goodman Group (ASX:GMG) up more than 4%, Scentre Group (ASX:SCG) up nearly 3% and Stockland (ASX:SGP), up nearly 2% as US...
Miramar upgrades target within WA's Gidji, suggests extension to Northern Star's 8 Mile Dam Miramar Resources Ltd has updated its 8-Mile target within the Gidji project in WA based on recent reprocessing of data.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.